BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18803921)

  • 1. [Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT].
    Hernández Vara J; Rubiera del Fueyo M; Lorenzo Bosquet C; Castell Conesa J; Molina Cateriano CA; Rodríguez FM
    Med Clin (Barc); 2008 Sep; 131(8):285-9. PubMed ID: 18803921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.
    Lobsien E; Schreiner S; Plotkin M; Kupsch A; Schreiber SJ; Doepp F
    Mov Disord; 2012 Mar; 27(3):450-3. PubMed ID: 22237792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the substantia nigra echogenicity and
    Mašková J; Školoudík D; Štofaniková P; Ibarburu V; Kemlink D; Zogala D; Trnka J; Krupička R; Šonka K; Růžička E; Dušek P
    Sleep Med; 2020 Jun; 70():116-123. PubMed ID: 32403038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease.
    Li DH; Zhang LY; Hu YY; Jiang XF; Zhou HY; Yang Q; Kang WY; Liu J; Chen SD
    Parkinsonism Relat Disord; 2015 Aug; 21(8):923-8. PubMed ID: 26066091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcranial sonography and (123)I-FP-CIT single photon emission computed tomography in movement disorders.
    Bártová P; Kraft O; Bernátek J; Havel M; Ressner P; Langová K; Herzig R; Skoloudík D
    Ultrasound Med Biol; 2014 Oct; 40(10):2365-71. PubMed ID: 25194454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
    Spiegel J; Hellwig D; Möllers MO; Behnke S; Jost W; Fassbender K; Samnick S; Dillmann U; Becker G; Kirsch CM
    Brain; 2006 May; 129(Pt 5):1188-93. PubMed ID: 16513685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor.
    Doepp F; Plotkin M; Siegel L; Kivi A; Gruber D; Lobsien E; Kupsch A; Schreiber SJ
    Mov Disord; 2008 Feb; 23(3):405-10. PubMed ID: 18067184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.
    Zhou HY; Sun Q; Tan YY; Hu YY; Zhan WW; Li DH; Wang Y; Xiao Q; Liu J; Chen SD
    Parkinsonism Relat Disord; 2016 Mar; 24():28-33. PubMed ID: 26842545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
    Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
    Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. a preliminary observation.
    Pedroso JL; Bor-Seng-Shu E; Felicio AC; Braga-Neto P; Dutra LA; de Aquino CC; Ferraz HB; do Prado GF; Teixeira MJ; Barsottini OG
    J Neurol Sci; 2012 Aug; 319(1-2):59-62. PubMed ID: 22632781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Sprenger FS; Wurster I; Seppi K; Stockner H; Scherfler C; Sojer M; Schmidauer C; Berg D; Poewe W
    Mov Disord; 2016 Apr; 31(4):579-83. PubMed ID: 26893155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperechogenicity of the substantia nigra in Parkinson's disease.
    Ressner P; Skoloudík D; Hlustík P; Kanovský P
    J Neuroimaging; 2007 Apr; 17(2):164-7. PubMed ID: 17441838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the substantia nigra by means of transcranial ultrasound imaging].
    Vivo-Orti MN; Tembl JI; Sastre-Bataller I; Vazquez-Costa JF; Sahuquillo P; Burguera JA
    Rev Neurol; 2013 Mar; 56(5):268-74. PubMed ID: 23440754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcranial sonography in Parkinson's disease.
    Bor-Seng-Shu E; Pedroso JL; Andrade DC; Barsottini OG; Andrade LA; Barbosa ER; Teixeira MJ
    Einstein (Sao Paulo); 2012; 10(2):242-6. PubMed ID: 23052464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.